Proteins in cancer multidrug resistance;Bialka w opornos̈ci wielolekowej nowotworów

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 68, Issue , 2014, Pages 616-632

  Popęda, Marta ^a   Pluciennik, Elzbieta ^a   Bednarek, Andrzej K ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; Cancer cell; Chemotherapy; Detoxification; Membrane transporter; Multidrug resistance

Indexed keywords

CARRIER PROTEIN; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; GLUTATHIONE TRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; TUMOR ANTIGEN;

DRUG RESISTANCE; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; NEOPLASMS; PHYSIOLOGY;

ANTIGENS, NEOPLASM; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE TRANSFERASE; HUMANS; MEMBRANE TRANSPORT PROTEINS; NEOPLASMS; P-GLYCOPROTEIN;

EID: 84908265345     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1103268     Document Type: Review

References (107)

1. Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., Harrell P.M., Trinh Y.T., Zhang Q., Urbatsch I.L., Chang G.: Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science, 2009; 323: 1718-1722
2. Anderson J.M., Heindl L.M., Bauman P.A., Ludi C.W., Dalton W.S., Cress A.E.: Cytokeratin expression results in a drug-resistant phenotype to six different chemotherapeutic agents. Clin. Cancer Res., 1996; 2: 97-105
3. Asano T., Nakamura K., Fujii H., Horichi N., Ohmori T., Hasegawa K., Isoe T., Adachi M., Otake N., Fukunaga Y.: Altered expression of topoisomerase IIα contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation. Br. J. Cancer, 2005; 92: 1486-1492
4. Ban N., Takahashi Y., Takayama T., Kura T., Katahira T., Sakamaki S., Niitsu Y.: Transfection of glutathione S-Transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res., 1996; 56: 3577-3582
5. Bauman P.A., Dalton W.S., Anderson J.M., Cress A.E.: Expression of cytokeratin confers multiple drug resistance. Proc. Natl. Acad. Sci. USA, 1994; 91: 5311-5314
6. Beck W.T., Morgan S.E., Mo Y.Y., Bhat U.G.: Tumor cell resistance to DNA topoisomerase II inhibitors: New developments. Drug Resist. Updat., 1999; 2: 382-389
7. Bhargavi R., Vishwakarma S., Murty U.S.: Modeling analysis of GST (glutathione-S-Transferases) from Wuchereria bancrofti and Brugia malayi. Bioinformation, 2005; 1: 25-27
8. Borowski E., Bontemps-Gracz M.M., Piwkowska A.: Strategies for overcoming ABC-Transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim. Pol., 2005; 52: 609-627
9. Borst P., Evers R., Kool M., Wijnholds J.: A family of drug transporters: The multidrug resistance-Associated proteins. J. Natl. Cancer Inst., 2000; 92: 1295-1302
10. Bouhamyia L., Chantot-Bastaraud S., Zaidi S., Roynard P., Prengel C., Bernaudin J.F., Fleury-Feith J.: Immunolocalization and cell expression of lung resistance-related protein (LRP) in normal and tumoral human respiratory cells. J. Histochem. Cytochem., 2007; 55: 773-782
11. Bredel M.: Anticancer drug resistance in primary human brain tumors. Brain Res. Brain Res. Rev., 2001; 35: 161-204
12. Caulin C., Salvesen G.S., Oshima R.G.: Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J. Cell Biol., 1997; 138: 1379-1394
13. Chen Z.S., Tiwari A.K.: Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J., 2011; 278: 3226-3245
14. Chun J.H., Kim H.K., Kim E., Kim I.H., Kim J.H., Chang H.J., Choi I.J., Lim H.S., Kim I.J., Kang H.C., Park J.H., Bae J.M., Park J.G.: Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer Res., 2004; 64: 4703-4706
15. Clifford S.C., Neal D.E., Lunec J.: Alterations in expression of the multidrug resistance-Associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder. Br. J. Cancer, 1996; 73: 659-666
16. Cress A.E., Dalton W.S.: Multiple drug resistance and intermediate filaments. Cancer Metastasis Rev., 1996; 15: 499-506
17. Dai C.L., Tiwari A.K., Wu C.P., Su X.D., Wang S.R., Liu D.G., Ashby C.R.Jr., Huang Y., Robey R.W., Liang Y.J., Chen L.M., Shi C.J., Ambudkar S.V., Chen Z.S., Fu L.W.: Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res., 2008; 68: 7905-7914
18. Dalton W.S., Scheper R.J.: Lung resistance-related protein: Determining its role in multidrug resistance. J. Natl. Cancer Inst., 1999; 91: 1604-1605
19. Davis S.R., Cousins R.J.: Metallothionein expression in animals: A physiological perspective on function. J. Nutr., 2000; 130: 1085-1088
20. Demant E.J., Sehested M., Jensen P.B.: A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated anthracycline transport in multidrug-resistant tumor cells. Biochim. Biophys. Acta, 1990; 1055: 117-125
21. Depeille P., Cuq P., Mary S., Passagne I., Evrard A., Cupissol D., Vian L.: Glutathione S-Transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. Mol. Pharmacol., 2004; 65: 897-905
22. Depeille P., Cuq P., Passagne I., Evrard A., Vian L.: Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Br. J. Cancer, 2005; 93: 216-223
23. Dusinska M., Staruchova M., Horska A., Smolkova B., Collins A., Bonassi S., Volkovova K.: Are glutathione S transferases involved in DNA damage signalling? Interactions with DNA damage and repair revealed from molecular epidemiology studies. Mutat. Res., 2012; 736: 130-137
24. Eilers M., Roy U., Mondal D.: MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells. Exp. Biol. Med., 2008; 233: 1149-1160
25. Ferte J.: Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur. J. Biochem., 2000; 267: 277-294
26. Filipits M., Drach J., Pohl G., Schuster J., Stranzl T., Ackermann J., Konigsberg R., Kaufmann H., Gisslinger H., Huber H., Ludwig H., Pirker R.: Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin. Cancer Res., 1999; 5: 2426-2430
27. Ford J. M., Hait W.N.: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev., 1990; 42: 155-199
28. Fortune J.M., Osheroff N.: Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice. Prog. Nucleic Acid Res. Mol. Biol., 2000; 64: 221-253
29. Goldstein L.J., Galski H., Fojo A., Willingham M., Lai S.L., Gazdar A., Pirker R., Green A., Crist W., Brodeur G.M.: Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst., 1989; 81: 116-124
30. Hall M.D., Handley M.D., Gottesman M.M.: Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol. Sci., 2009; 30: 546-556
31. Hasegawa S., Abe T., Naito S., Kotoh S., Kumazawa J., Hipfner D.R., Deeley R.G., Cole S.P., Kuwano M.: Expression of multidrug resistance-As sociated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br. J. Cancer, 1995; 71: 907-913
32. Hayes J.D., Flanagan J.U., Jowsey I.R.: Glutathione transferases. Annu. Rev. Pharmacol. Toxicol., 2005; 45: 51-88
33. Hochhauser D., Kotecha M., O'Hare C., Morris P.J., Hartley J.M., Taherbhai Z., Harris D., Forni C., Mantovani R., Lee M., Hartley J.A.: Modulation of topoisomerase IIα expression by a DNA sequence-specific polyamide. Mol. Cancer Ther., 2007; 6: 346-354
34. Hoffmann U., Kroemer H.K.: The ABC transporters MDR1 and MRP2: Multiple functions in disposition of xenobiotics and drug resistance. Drug Metab. Rev., 2004; 36: 669-701
35. Hollt V., Kouba M., Dietel M., Vogt G.: Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem. Pharmacol., 1992; 43: 2601-2608
36. Islam T., Berhane K., McConnell R., Gauderman W.J., Avol E., Peters J.M., Gilliland F.D.: Glutathione-S-Transferase (GST) P1, GSTM1, exercise, ozone and asthma incidence in school children. Thorax, 2009; 64: 197-202
37. Jedlitschky G., Keppler D.: Transport of leukotriene C4 and structurally related conjugates. Vitam. Horm., 2002; 64: 153-184
38. Jones P.M., George A.M.: Mechanism of ABC transporters: A molecular dynamics simulation of a well characterized nucleotide-binding subunit. Proc. Natl. Acad. Sci. USA, 2002; 99: 12639-12644
39. Juliano R.L., Ling V.: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 1976; 455: 152-162
40. Kanaji N., Bandoh S., Fujita J., Ishii T., Ishida T., Kubo A.: Compensation of type I and type II cytokeratin pools in lung cancer. Lung Cancer, 2007; 55: 295-302
41. Kellen J.A.: The reversal of multidrug resistance: An update. J. Exp. Ther. Oncol., 2003; 3: 5-13
42. Kizek R., Adam V., Hrabeta J., Eckschlager T., Smutny S., Burda J.V., Frei E., Stiborova M.: Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances. Pharmacol. Ther., 2012; 133: 26-39
43. Krishnakumar S., Mallikarjuna K., Desai N., Muthialu A., Venkatesan N., Sundaram A., Khetan V., Shanmugam M.P.: Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. Br. J. Ophthalmol., 2004; 88: 1521-1526
44. Ku N.O., Omary M.B.: Effect of mutation and phosphorylation of type I keratins on their caspase-mediated degradation. J. Biol. Chem., 2001; 276: 26792-26798
45. Kuo M.T.: Redox regulation of multidrug resistance in cancer chemotherapy: Molecular mechanisms and therapeutic opportunities. Antioxid. Redox. Signal., 2009; 11: 99-133
46. Lampidis T.J., Krishan A., Planas L., Tapiero H.: Reversal of intrinsic resistance to adriamycin in normal cells by verapamil. Cancer Drug Deliv., 1986; 3: 251-259
47. Lau A.T., Chiu J.F.: The possible role of cytokeratin 8 in cadmium-induced adaptation and carcinogenesis. Cancer Res., 2007; 67: 2107-2113
48. Lehne G.: P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr. Drug Targets, 2000; 1: 85-99
49. Leonard G.D., Fojo T., Bates S.E.: The role of ABC transporters in clinical practice. Oncologist, 2003; 8: 411-424
50. Leslie E.M., Deeley R.G., Cole S.P.: Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol., 2005; 204: 216-237
51. Ling V.: Multidrug resistance: Molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol., 1997; 40, Suppl: S3-S8
52. Liscovitch M., Lavie Y.: Cancer multidrug resistance: A review of recent drug discovery research. Drugs, 2002; 5: 349-355
53. Litman T., Druley T.E., Stein W.D., Bates S.E.: From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci., 2001; 58: 931-959
54. Liu F., Chen Z., Wang J., Shao X., Cui Z., Yang C., Zhu Z., Xiong D.: Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. Neoplasia, 2008; 10: 1275-1284
55. Locher K.P.: Review. Structure and mechanism of ATP-binding cassette transporters. Philos. Trans. R. Soc. Lond. B Biol. Sci., 2009; 364: 239-245
56. Luqmani Y.A.: Mechanisms of drug resistance in cancer chemotherapy. Med. Princ. Pract., 2005; 14, Suppl. 1: 35-48
57. Meyer K.N., Kjeldsen E., Straub T., Knudsen B.R., Hickson I.D., Kikuchi A., Kreipe H., Boege F.: Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities. J. Cell Biol., 1997; 136: 775-788
58. Mitra P., Audus K.L.: MRP isoforms and BCRP mediate sulfate conjugate efflux out of BeWo cells. Int. J. Pharm., 2010; 384: 15-23
59. Mitropoulos D., Kyroudi-Voulgari A., Theocharis S., Serafetinides E., Moraitis E., Zervas A., Kittas C.: Prognostic significance of metallothionein expression in renal cell carcinoma. World J. Surg. Oncol., 2005; 3: 5
60. Monge M., Vilaseca M., Soto-Cerrato V., Montaner B., Giralt E., Perez-Tomas R.: Proteomic analysis of prodigiosin-induced apoptosis in a breast cancer mitoxantrone-resistant (MCF-7 MR) cell line. Invest New Drugs., 2007; 25: 21-29
61. Morrow C.S., Smitherman P.K., Diah S.K., Schneider E., Townsend A.J.: Coordinated action of glutathione S-Transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1 -And MRP1-Associated resistance to chlorambucil in MCF7 breast carcinoma cells. J. Biol. Chem., 1998; 273: 20114-20120
62. Mossink M.H., van Zon A., Scheper R.J., Sonneveld P., Wiemer E.A.: Vaults: A ribonucleoprotein particle involved in drug resistance? Oncogene, 2003; 22: 7458-7467
63. Ni Z., Bikadi Z., Rosenberg M.F., Mao Q.: Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr. Drug Metab., 2010; 11: 603-617
64. Nitiss J.L.: Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer, 2009; 9: 338-350
65. Omary M.B., Ku N.O., Strnad P., Hanada S.: Toward unraveling the complexity of simple epithelial keratins in human disease. J. Clin. Invest., 2009; 119: 1794-1805
66. Oshima R.G.: Apoptosis and keratin intermediate filaments. Cell Death Differ., 2002; 9: 486-492
67. Pajeva I.K., Wiese M.: Structure-Activity relationships of tariquidar analogs as multidrug resistance modulators. AAPS J., 2009; 11: 435-444
68. Parekh H.K., Simpkins H.: The differential expression of cytokeratin 18 in cisplatin-sensitive and -resistant human ovarian adenocarcinoma cells and its association with drug sensitivity. Cancer Res., 1995; 55: 5203-5206
69. Pasello M., Michelacci F., Scionti I., Hattinger C.M., Zuntini M., Caccuri A.M., Scotlandi K., Picci P., Serra M.: Overcoming glutathione S-Transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res., 2008; 68: 6661-6668
70. Paumi C.M., Chuk M., Snider J., Stagljar I., Michaelis S.: ABC transporters in Saccharomyces cerevisiae and their interactors: New technology advances the biology of the ABCC (MRP) subfamily. Microbiol. Mol. Biol. Rev., 2009; 73: 577-593
71. Peaston A.E., Gardaneh M., Franco A.V., Hocker J.E., Murphy K.M., Farnsworth M.L., Catchpoole D.R., Haber M., Norris M.D., Lock R.B., Marshall G.M.: MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells. Br. J. Cancer, 2001; 85: 1564-1571
72. Perez-Tomas R.: Multidrug resistance: Retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem., 2006; 13: 1859-1876
73. Podolski-Renic A., Jadranin M., Stankovic T., Bankovic J., Stojkovic S., Chiourea M., Aljancic I., Vajs V., Tesevic V., Ruzdijic S., Gagos S., Tanic N., Pesic M.: Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing. Cancer Chemother. Pharmacol., 2013; 72: 683-697
74. Raguz S., Yague E.: Resistance to chemotherapy: New treatments and novel insights into an old problem. Br. J. Cancer, 2008; 99: 387-391
75. Raidl M., Berger W., Schulte-Hermann R., Kandioler-Eckersberger D., Kappel S., Wrba F., Micksche M., Grasl-Kraupp B.: Expression of the lung resistance-related protein in human and rat hepatocarcinogenesis. Am. J. Physiol Gastrointest. Liver Physiol., 2002; 283: G1117-G1124
76. Robey R.W., Massey P.R., Amiri-Kordestani L., Bates S.E.: ABC transporters: Unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med. Chem., 2010; 10: 625-633
77. Ross D.D.: Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract. Res. Clin. Haematol., 2004; 17: 641-651
78. Ruwali M., Singh M., Pant M.C., Parmar D.: Polymorphism in glutathione S-Transferases: Susceptibility and treatment outcome for head and neck cancer. Xenobiotica, 2011; 41: 1122-1130
79. Sakoda L.C., Blackston C.R., Xue K., Doherty J.A., Ray R.M., Lin M.G., Stalsberg H., Gao D.L., Feng Z., Thomas D.B., Chen C.: Glutathione S-Transferase M1 and P1 polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women. Breast Cancer Res. Treat., 2008; 109: 143-155
80. Sankatsing S.U., Beijnen J.H., Schinkel A.H., Lange J.M., Prins J.M.: P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob. Agents Chemother., 2004; 48: 1073-1081
81. Satoh M., Cherian M.G., Imura N., Shimizu H.: Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res., 1994; 54: 5255-5257
82. Scheffer G.L., Wijngaard P.L., Flens M.J., Izquierdo M.A., Slovak M.L., Pinedo H.M., Meijer C.J., Clevers H.C., Scheper R.J.: The drug resistance-related protein LRP is the human major vault protein. Nat. Med., 1995; 1: 578-582
83. Schneider E., Horton J.K., Yang C.H., Nakagawa M., Cowan K.H.: Multidrug resistance-Associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res., 1994; 54: 152-158
84. Schoeffler A.J., Berger J.M.: Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism. Biochem. Soc. Trans., 2005; 33: 1465-1470
85. Shen F., Chu S., Bence A.K., Bailey B., Xue X., Erickson P.A., Montrose M.H., Beck W.T., Erickson L.C.: Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J. Pharmacol. Exp. Ther., 2008; 324: 95-102
86. Simon S.M., Schindler M.: Cell biological mechanisms of multidrug resistance in tumors. Proc. Natl. Acad. Sci. USA, 1994; 91: 3497-3504
87. Singh A., Wu H., Zhang P., Happel C., Ma J., Biswal S.: Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol. Cancer Ther., 2010; 9: 2365-2376
88. Skarda J., Hajduch M., Kolek V.: Drug resistance in lung cancer. Cancer Ther., 2008; 6: 377-388
89. Stavrovskaya A.A.: Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc.), 2000; 65: 95-106
90. Stavrovskaya A.A., Stromskaya T.P.: Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry (Mosc.), 2008; 73: 592-604
91. Stefkova J., Poledne R., Hubacek J.A.: ATP-binding cassette (ABC) transporters in human metabolism and diseases. Physiol Res., 2004; 53: 235-243
92. Takahashi K., Shibata T., Oba T., Ishikawa T., Yoshikawa M., Tatsunami R., Takahashi K., Tampo Y.: Multidrug-resistance-Associated protein plays a protective role in menadione-induced oxidative stress in endothelial cells. Life Sci., 2009; 84: 211-217
93. Tew K.D.: Glutathione-Associated enzymes in anticancer drug resistance. Cancer Res., 1994; 54: 4313-4320
94. Thirumoorthy N., Shyam S.A., Manisenthil K.K., Senthil K.M., Ganesh G., Chatterjee M.: A review of metallothionein isoforms and their role in pathophysiology. World J. Surg. Oncol., 2011; 20; 9: 54
95. Turner J.G., Gump J.L., Zhang C., Cook J.M., Marchion D., Hazlehurst L., Munster P., Schell M.J., Dalton W.S., Sullivan D.M.: ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood, 2006; 108: 3881-3889
96. Ullah M.F.: Cancer multidrug resistance (MDR): A major impediment to effective chemotherapy. Asian Pac. J. Cancer Prev., 2008; 9: 1-6
97. Vasak M.: Advances in metallothionein structure and functions. J. Trace Elem. Med. Biol., 2005; 19: 13-17
98. Vasiliou V., Vasiliou K., Nebert D.W.: Human ATP-binding cassette (ABC) transporter family. Hum. Genomics, 2009; 3: 281-290
99. Vilaboa N.E., Galan A., Troyano A., de Blas E., Aller P.: Regulation of multidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). J. Biol. Chem., 2000; 275: 24970-24976
100. Volm M., Kastel M., Mattern J., Efferth T.: Expression of resistance factors (P-glycoprotein, glutathione S-Transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer, 1993; 71: 3981-3987
101. Weinlich G., Eisendle K., Hassler E., Baltaci M., Fritsch P.O., Zelger B.: Metallothionein -overexpression as a highly significant prognostic factor in melanoma: A prospective study on 1270 patients. Br. J. Cancer, 2006; 94: 835-841
102. Weng Y.R., Cui Y., Fang J.Y.: Biological functions of cytokeratin 18 in cancer. Mol. Cancer Res., 2012; 10: 485-493
103. Wilstermann A.M., Osheroff N.: Base excision repair intermediates as topoisomerase II poisons. J. Biol. Chem., 2001; 276: 46290-46296
104. Wyler B., Shao Y., Schneider E., Cianfriglia M., Scheper R.J., Frey B.M., Gieseler F., Schmid L., Twentyman P.R., Lehnert M.: Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-Associated multidrug resistance in RPMI 8226 human myeloma cells. Br. J. Haematol., 1997; 97: 65-75
105. Yan S., Shun-Chang J., Li C., Jie L., Ya-Li L., Ling-Xiong W.: Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer. BMC Cancer, 2010; 10: 621
106. Yang K., Wu J., Li X.: Recent advances in the research of P-glycoprotein inhibitors. Biosci. Trends, 2008; 2: 137-146
107. Zhan M., Yu D., Liu J., Glazer R.I., Hannay J., Pollock R.E.: Transcriptional repression of protein kinase Cα via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. J. Biol. Chem., 2005; 280: 4825-4833